At the recently concluded "Annual Grand Event" in the field of urology—the 32nd Annual Meeting of the Urological Association of the Chinese Medical Association (CUA2025)—Professor Yang Xuecheng, Director of the Department of Urology at Qingdao U

On August 11, 2025, the Phase II clinical trial of Injection DGPR1008—a near-infrared tumor-targeted fluorescent contrast agent independently developed by SIGNDO Biotechnology (Suzhou) Co., Ltd. (hereinafter referred to as "SIGNDO Biotechnology"

Innovative drugs, Suzhou News

Recently, Jing Zhao, the founder and general manager of SIGNDO (Suzhou) Co., Ltd. (hereinafter referred to as "SIGNDO"), accompanied by Lizhi Zhang, the chief medical officer, and Ying Xu, the marketing director of SIGNDO, engaged in in-depth di

On October 31, 2024, SIGNDO Biotech (Suzhou) Co., Ltd. (hereinafter referred to as "SIGNDO Biotech") announced that its independently developed DGPR1008 injection, a near-infrared tumor-targeted fluorescent contrast agent with independent intell

SIGNDO Biotech announced that the first-in- class batch of subjects has been enrolled and dosed in the Phase I clinical trial of DGPR1008 Injection, the first-in-class near-infrared tumor-targeted fluorescent contrast agent product to receive clinical app

First-in-class near-infrared tumor-targeted fluorescent contrast agent clinical trial has been approved, filling a gap in this field within China!

On March 7, 2024, according to public information from the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the Investigational New Drug (IND) application for "DGPR1008 Injection" submitted by SIGNDO Biotechnolog

Recently, SIGNDO Biotechnology (Suzhou) Co., Ltd. (referred to as "SIGNDO Biotech") announced the completion of a Pre-A round of financing, raising tens of millions of RMB.